Business
5N Plus Expands its Active Pharmaceutical Ingredient (API) Portfolio to Include Compounds for a New Class of Antibiotic & Antibiofilm Drugs
5N Plus Expands its Active Pharmaceutical Ingredient (API) Portfolio to Include Compounds...
About this update from 5n Plus Inc.
[{"type":"text","content":"\n \n \n \n 5N Plus Expands its Active Pharmaceutical Ingredient (API) Portfolio to Include Compounds for a New Class of Antibiotic & Antibiofilm Drugs\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n 5N Plus Expands its Active Pharmaceutical Ingredient (API) Portfolio to Include Compounds for a New Class of Antibiotic & Antibiofilm Drugs\n \n \n Canada NewsWire\n \n \n \n \n \n MONTREAL\n \n ,\n \n Jan. 12, 2021\n \n /CNW/ - 5N Plus Inc. (\"5N Plus\" or the \"Company\"), a leading global producer of specialty chemicals and engineered materials, announced today that it has entered into a strategic agreement with\n \n Bozeman, Montana\n \n -based Microbion Corporation (\"Microbion\"), aimed at furthering the development of Microbion's new class of antibiotic and antibiofilm drugs. Under the terms of the agreement, 5N Plus has taken an equity stake in Microbion and will assume responsibility for the manufacturing of Bismuth-based Active Pharmaceutical Ingredients (API) required in Microbion's family of drug products currently under development, including Pravibismane, the API in the company's lead drug product.\n \n \n 5N Plus is uniquely positioned to support Microbion in developing and manufacturing Active Pharmaceutical Ingredients essential for its new class of antibiotic and antibiofilm drug products. 5N Plus is the world's leading producer of Active Pharmaceutical Ingredients based on Bismuth compounds. In\n \n December 2017\n \n , the Company announced its entry into active additives for the health and nutrition industry (Refer to: 5N Plus Press Release\n \n December 7, 2017\n \n ), building on its pharmaceutical background, and within 18 months commissioned a new production plant in\n \n Germany\n \n to support this initiative. In 2020, the Company finalized a series of investments which expanded capacity and improved capability of its pharmaceutical facility in Lübeck,\n \n Germany\n \n (Refer to: 5N Plus Press Release\n \n October 28\n \n , 2020).  The Company's site in Lübeck manufactures a portfolio of Active Pharmaceutical I...